# Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

> **NCT03945773** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 127 (actual)

## Conditions studied

- Locally Advanced or Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT03945773
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-08
- **Primary completion:** 2023-05-11
- **Final completion:** 2026-02-12
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945773, "Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03945773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*